African trypanosomiasis historical perspective: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 11: Line 11:
*In 1898, Brault suggested [[trypanosomes]] as the cause of [[sleeping sickness]].
*In 1898, Brault suggested [[trypanosomes]] as the cause of [[sleeping sickness]].
*In 1901, Forde and Dutton described [[Trypanosoma brucei gambiense|''Trypanosoma brucei gambiense'']] in human [[blood]] for the first time.
*In 1901, Forde and Dutton described [[Trypanosoma brucei gambiense|''Trypanosoma brucei gambiense'']] in human [[blood]] for the first time.
*In 1902, the First and second [[Sleeping Sickness]] Commissions led by Low and Bruce were conducted in Uganda.
*In 1902, the First and Second [[Sleeping Sickness]] Commissions led by Low and Bruce were conducted in Uganda.
*In 1902, Castellani identified [[trypanosomes]] in [[cerebrospinal fluid]] of [[sleeping sickness]] patients for the first time.
*In 1902, Castellani identified [[trypanosomes]] in the [[cerebrospinal fluid]] of [[sleeping sickness]] patients for the first time.
*In 1902, Laveran and Mesnil discovered that sodium arsenite can be used to kill [[trypanosomes]].
*In 1902, Laveran and Mesnil discovered that sodium arsenite can be used to kill [[trypanosomes]].
*In 1903, David Bruce recognized the [[tsetse fly]] as the [[arthropod]] [[Vector (biology)|vector]].
*In 1903, David Bruce recognized the [[tsetse fly]] as the [[arthropod]] [[Vector (biology)|vector]].
Line 22: Line 22:
*In 1949, [[melarsoprol]] was used for the first time as an anti-trypanosome drug.
*In 1949, [[melarsoprol]] was used for the first time as an anti-trypanosome drug.
*In 1969, Vickerman described the coat of [[trypanosomes]] as the source of [[antigenic variation]].
*In 1969, Vickerman described the coat of [[trypanosomes]] as the source of [[antigenic variation]].
*In 1992, [[Eflornithine]] was used for the treatment of human [[Sleeping sickness (patient information)|sleeping sickness]].
*In 1992, [[eflornithine]] was used for the treatment of human [[Sleeping sickness (patient information)|sleeping sickness]].


==References==
==References==

Revision as of 19:20, 9 August 2017

African trypanosomiasis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating African trypanosomiasis from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT Scan

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

African trypanosomiasis historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of African trypanosomiasis historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on African trypanosomiasis historical perspective

CDC on African trypanosomiasis historical perspective

African trypanosomiasis historical perspective in the news

Blogs on African trypanosomiasis historical perspective

Directions to Hospitals Treating African trypanosomiasis

Risk calculators and risk factors for African trypanosomiasis historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Pilar Almonacid; Aditya Ganti M.B.B.S. [2]

Overview

African trypanosomiasis has been present in Africa for thousands of years. In 1903, David Bruce identified the causative agent vector. In 1910, the differentiation between the subspecies of the protozoa was established.

Historical Perspective

References

  1. Cox FE (2004). "History of sleeping sickness (African trypanosomiasis)". Infect. Dis. Clin. North Am. 18 (2): 231–45. doi:10.1016/j.idc.2004.01.004. PMID 15145378.